UPB
NASDAQ
$6.98
Upstream Bio Inc (UPB)
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. The company is headquartered in Waltham, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $38.25 (+447.99%)
Market Cap
$396M
Free Cash Flow Yield
-35.42%
Beta (5Y)
1.09
Price Chart
Valuation
Market Cap$396M
P/S119.09
P/B1.28
Profitability
Total Revenue (TTM)$3.32M
Gross Profit (TTM)$3.32M
EBITDA-$172M
Operating Margin-4218%
EPS-$2.90
Financial Health
Free Cash Flow Yield-35.42%
Growth & Risk
Beta (5Y)1.09
Sharpe Ratio-0.01